We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Lensar Inc (LNSR) USD0.01

Sell:$6.97 Buy:$7.77 Change: $0.05 (0.68%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (0.68%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.05 (0.68%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It has developed the LENSAR Laser System to provide an alternative laser cataract treatment tool that allows the surgeon to better address astigmatism and improve visual outcomes. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The Company is also developing an integrated cataract treatment system, ALLY Adaptive Cataract Treatment System (ALLY). The ALLY system is designed to combine its existing femtosecond laser technology and a phacoemulsification system into a single unit that allows surgeons to perform each of the critical steps in a cataract procedure in a single operating room using this device.

Contact details

2800 Discovery Drive, Suite 100
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$77.33 million
Shares in issue:
10.99 million
Health Care Equipment
United States
US dollar

Key personnel

  • Nicholas Curtis
    Chief Executive Officer, Director
  • Thomas Staab
    Chief Financial Officer, Secretary
  • Alan Connaughton
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.